Onkologie 2020: 14(Suppl.B): 44-46 | DOI: 10.36290/xon.2020.036

Patient with metastatic malignant melanoma treated with pembrolizumab

Alena Fialová, Monika Arenbergerová
Dermatovenerologická klinika, Fakultní nemocnice Královské Vinohrady v Praze

The treatment of metastatic malignant melanoma includes treatment with anti-PD-1 antibodies (programmed cell death membrane protein), including pembrolizumab. There are different forms of malignant melanoma including acral malignant melanoma (ALM). ALM is associated with poorer prognosis and other biological behavior. There is less evidence of anti-PD-1 antibody efficacy on metastatic ALM than in other forms of melanoma. Our case report focuses on the good respons of pembrolizumab in case of a patient with acral metastatic malignant melanoma.

Keywords: case report, acral malignant melanoma, metastatic malignant melanoma, immunotherapy, checkpoint inhibitors, pembrolizumab.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fialová A, Arenbergerová M. Patient with metastatic malignant melanoma treated with pembrolizumab. Onkologie. 2020;14(Suppl.B / Onkologické kazuistiky 2):44-46. doi: 10.36290/xon.2020.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hamid O. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019 Apr; 30(4): 582-588. Go to original source... Go to PubMed...
    2. Schachter J, Ribas A, Long GV. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21; 390(10105): 1853-1862. Go to original source... Go to PubMed...
    3. Bello DM. Prognosis of acral melanoma: a series of 281 patientsAnn Surg Oncol. 2013 Oct; 20(11): 3618-25. Go to original source... Go to PubMed...
    4. Alexander N. Shoushtari, Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma Cancer. 2016 Nov 15; 122(21): 3354-3362. Go to original source... Go to PubMed...
    5. Gershenwald JE. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6): 472-492. Go to original source... Go to PubMed...
    6. Elia G. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2019 Dec 11: 101370. Go to original source... Go to PubMed...
    7. Moreira A. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017 Jan; 9(2): 115-121. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.